Details for Patent: 11,938,130

Which drugs does patent 11,938,130 protect, and when does it expire?

Patent 11,938,130 protects XOSPATA and is included in one NDA.

This patent has thirty patent family members in twenty-two countries.

Summary for Patent: 11,938,130

Title:	Stable pharmaceutical composition for oral administration
Abstract:	Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.
Inventor(s):	Masakazu Miyazaki, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
Assignee:	Astellas Pharma Inc
Application Number:	US18/316,357
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 11,938,130

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	XOSPATA	gilteritinib fumarate	TABLET;ORAL	211349-001	Nov 28, 2018		RX	Yes	Yes			Y

International Family Members for US Patent 11,938,130

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2989534
China	107847500
Denmark	3318259
European Patent Office	3318259
European Patent Office	4230208
Spain	2940306
Finland	3318259